La Jolla, CALIFORNIA5 Active Studies

Geographic Atrophy Clinical Trials in La Jolla, CALIFORNIA

Find 5 actively recruiting geographic atrophy clinical trials in La Jolla, CALIFORNIA. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
2,572
Enrolling

Recruiting Geographic Atrophy Studies in La Jolla

RecruitingLa Jolla, CALIFORNIANCT06393374

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TP...

1,530 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingLa Jolla, CALIFORNIANCT06764875

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

This is a Phase â…¢, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) c...

840 participants
AstraZeneca
View Study Details
RecruitingLa Jolla, CALIFORNIANCT06630234

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module...

120 participants
Deciphera Pharmaceuticals, LLC
View Study Details
RecruitingLa Jolla, CALIFORNIANCT06388083

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease...

60 participants
Belite Bio, Inc
View Study Details
RecruitingLa Jolla, CALIFORNIANCT05831176

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participan...

22 participants
Regeneron Pharmaceuticals
View Study Details

About Geographic Atrophy Clinical Trials in La Jolla

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 5 geographic atrophy clinical trials recruiting participants in La Jolla, CALIFORNIA. These studies are seeking a combined 2,572 participants. Research is being sponsored by Merck Sharp & Dohme LLC, AstraZeneca, Deciphera Pharmaceuticals, LLC and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in La Jolla — FAQ

Are there geographic atrophy clinical trials in La Jolla?

Yes, there are 5 geographic atrophy clinical trials currently recruiting in La Jolla, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in La Jolla?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you about next steps.

Are clinical trials in La Jolla free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Jolla studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 5 active trials in La Jolla are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated March 2, 2026 from ClinicalTrials.gov